Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTHA2-FAPI
- Development stage
- Preclinical
- Lead developer
- Université de Sherbrooke
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
64Cu-DOTHA2-FAPI (also referred to as 64Cu-DOTHA2-FAPI-04) is a novel radiolabeled small molecule fibroblast activation protein inhibitor (FAPI) developed for positron emission tomography (PET) imaging. It consists of the FAP-targeting ligand DOTHA2-FAPI (derived from the FAPI-04 scaffold) chelated with the positron-emitting radioisotope copper-64 (64Cu). The tracer specifically binds to fibroblast activation protein alpha (FAP), which is highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor stroma of various solid tumors, including head and neck squamous cell carcinoma (HNSCC), prostate cancer, and melanoma. Developed by researchers at the Université de Sherbrooke and the Centre d'Imagerie Moléculaire de Sherbrooke (CIMS), 64Cu-DOTHA2-FAPI is utilized in preclinical research to visualize tumor stroma, evaluate tumor heterogeneity, and monitor therapeutic responses to immunotherapies such as nivolumab.
- Other names
- 64Cu-labeled DOTHA2-FAPI[64Cu]Cu-DOTHA2-FAPI[64Cu]Cu-DOTHA2-FAPI-04copper-64 DOTHA2-FAPIcopper64 DOTHA2-FAPIcopper 64 DOTHA2-FAPI
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 64Cu-DOTHA2-FAPI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTHA2-FAPI.